Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR
The poster reports post-hoc results from the SAPHYR study on the resolution of PMR signs and symptoms regardless of glucocorticoid (GC) use and GC-free resolution of PMR signs and symptoms over time. GC-free resolution of PMR signs and symptoms was maintained from week 16 to week 52 in majority of patients treated with sarilumab 200mg Q2W + 14week GC.
Author(s):
- Robert Spiera Spiera
- Sebastian Unizony
- Kenneth J. Warrington
- Jennifer Sloane Lazar
- Angeliki Glannelou
- Michael C Nivens
- Bolanie Akinlade
- Wanling Wong
- Yong Lin
- Frank R Buttgereit, MD
- Valerie Devauchelle-Pensec
- Andrea Rubbert-Roth
- Bhaskar Dasgupta
| Display Label | Action |
|---|